Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

NCT01511692 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of the medication liraglutide to glimepiride on appetite in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 43 people

Who can join Ages 18–65 · all sexes

Timeline Started 2005-11 · est. completion 2007-09

Where 2 sites · Australia, Germany

What this study is testing ClinicalTrials.gov NCT01511692 ↗

Description as written by the study sponsor.

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.

Treatments tested

liraglutide Drug

1.8 mg/day injected subcutaneously for 4 weeks
placebo Drug

Liraglutide placebo, injected subcutaneously for 4 weeks
placebo Drug

Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
glimepiride Drug

Dose individually adjusted, administered orally for 4 weeks

Main thing measured	The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01511692 ↗